Oxford Events, the new replacement for OxTalks, will launch on 16th March. From now until the launch of Oxford Events, new events cannot be published or edited on OxTalks while all existing records are migrated to the new platform. The existing OxTalks site will remain available to view during this period.
From 16th, Oxford Events will launch on a new website: events.ox.ac.uk, and event submissions will resume. You will need a Halo login to submit events. Full details are available on the Staff Gateway.
Over the last 30 years, there has been very little improvement in the age of diagnosis of Duchenne muscular dystrophy. Despite numerous advocacy organizations’ efforts and high profile campaigns to raise public and professional awareness of this condition, a persistent diagnostic odyssey remains.
In recent years, new therapeutic approaches aimed at restoring dystrophin expression have been developed and approved, while others are in clinical trials, including gene therapy.
Newborn screening for DMD has been piloted in a number of centers around the world. There is a renewed interest and support for the case of NBS for DMD as demonstrated by the recent submission of a nomination package to add Duchenne to the Recommended Uniform Screening Panel (RUSP) in the USA.
